Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03030066 : Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas
PhaseN/A
AgesMin: 20 Years Max: N/A
Eligibility
Inclusion Criteria:

1. Has histologically confirmed glioma with an IDH1-R132 mutation

2. Has disease that has recurred or progressed following standard treatment including
radiotherapy

3. Has measurable lesion(s) as per RANO criteria

4. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

Exclusion Criteria:

1. Has significant symptoms of increased intracranial pressure

2. Has another active neoplasm

3. Has active infection requiring systemic treatment

4. Has a history of severe cardiac disease

5. Has had prior treatment with any inhibitor targeting mutant IDH1

6. Has had investigational drug treatment within 4 weeks prior to the first dose of study
treatment

7. Is a pregnant or lactating female
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03030066      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740